Toronto, Ontario, Canada, April 2026 – Apotex Inc. has announced the appointment of Miguel Lerma as M&A Integration Project Manager, strengthening its capabilities in driving post-merger integration and value realization as the company continues to expand its global footprint in pharmaceuticals. In this role, Miguel will focus on leading integration programs, ensuring operational alignment, and delivering synergy capture across strategic acquisitions.
Prior to joining Apotex, Miguel Lerma served as Senior Project Manager, PMO at IPEX by Aliaxis, where he led strategic project portfolios with a strong focus on post-acquisition integration and cost optimization. He directed multimillion-dollar programs, led integration management offices, and delivered measurable cost efficiencies while maintaining operational continuity.
Earlier, he worked as Director – Value Creation (Growth Strategy and Execution) at PwC Canada, where he led operational due diligence, integration, and separation engagements across industries. His work included designing M&A playbooks, driving integration programs, and supporting private equity and corporate clients in achieving value creation through structured transformation initiatives.
Miguel also spent over six years with EY-Parthenon as Senior Manager – M&A Strategy and Transactions, where he played a key role in building integration and divestiture capabilities, leading complex cross-border M&A programs, and delivering synergy roadmaps and operational transformation outcomes across sectors.
Before this, he worked at Accenture as Manager – Business Transformation Strategy, where he led large-scale transformation and PMO initiatives across telecom, retail, and banking sectors, driving operational improvements and process optimization.
He began his career with roles at Ixe Grupo Financiero, Abbott Laboratories, and Eli Lilly and Company, where he built strong expertise in business intelligence, capital project execution, and operational efficiency within regulated and high-performance environments.
Apotex Inc. is a global pharmaceutical company dedicated to improving access to affordable, innovative medicines and health products. Headquartered in Toronto, Canada, Apotex offers a broad portfolio of over 550 generic, biosimilar, and innovative medicines, along with more than 225 natural health products.
As the largest Canadian-based pharmaceutical company, Apotex operates as a key health partner across the Americas, supporting pharmaceutical licensing, product acquisitions, and global healthcare delivery with a strong focus on innovation, accessibility, and patient outcomes.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
